证券代码：300937 证券简称：药易购 公告编号：2024-038 四川合纵药易购医药股份有限公司 第三届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 四川合纵药易购医药股份有限公司（以下简称"公司"）第三届董事会第二十 四次会议于 2024 年 10 月 24 日在公司会议室以现场结合通讯表决的方式召开。 本次董事会会议通知于 2024 年 10 月 18 日以书面、电话方式通知全体董事。会 议应出席董事 8 名，实际出席董事 8 名，其中独立董事罗响、刘磊、邓博夫以通 讯表决方式出席。本次董事会会议由董事长李燕飞女士主持，公司监事、高级管 理人员列席了本次会议。本次会议的召集和召开符合国家有关法律、行政法规、 部门规章、规范性文件及《四川合纵药易购医药股份有限公司章程》的规定。 二、董事会会议审议情况 经与会董事审议，以投票表决方式审议了以下议案： 1、审议通过《关于公司 2024 年第三季度报告全文的议案》 董事会认为《2024 年第三季度报告》全文的编制和审议程序符合法律法规和 中国证监会、深圳 ...

二、精诚名医的基本情况 （一）基本情况 证券代码：300937 证券简称：药易购 公告编号：2024-040 四川合纵药易购医药股份有限公司 关于控股子公司减资暨少数股东退出的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开第三届董事会第二十四次会议，审议通过了《关于控股子公司减资暨 少数股东退出的议案》。现将有关情况公告如下： 一、本次减资事项概述 公司控股子公司四川精诚名医医疗股份有限公司（以下简称"精诚名医"） 注册资本 2,300 万元，其中公司持有其 51.3209%股权。精诚名医的部分少数股东 成都妙济企业管理合伙企业（有限合伙）（以下简称"成都妙济"）及青曦等三位 自然人股东拟通过减资方式退出，不再持有精诚名医股权，共减少对精诚名医出 资 981.62 万元，减资对价 1,295.03 万元。本次事项不会导致公司合并报表范围 发生变化，公司对精诚名医的出资额不变，本次减资完成后，精诚名医注册资本 将由 2,300 万元减少至 1,318.38 万元，公 ...

Financial Performance - The company's revenue for Q3 2024 was ¥1,010,149,855.81, representing a year-over-year increase of 0.26%[3] - Net profit attributable to shareholders decreased by 46.63% year-over-year to ¥1,835,713.94, while the net profit after deducting non-recurring gains and losses fell by 69.25% to ¥884,089.15[3] - The total operating revenue for the third quarter was CNY 3,235,469,610.27, a slight increase from CNY 3,212,357,594.74 in the previous year, representing a growth of approximately 0.72%[15] - The net profit for Q3 2024 was CNY 10,473,171.26, a decrease from CNY 49,645,720.30 in Q3 2023, representing a decline of approximately 78.9%[16] - The total operating profit for Q3 2024 was CNY 10,234,621.40, down from CNY 60,045,240.85 in the same period last year, indicating a decrease of about 83.0%[16] - The total comprehensive income attributable to the parent company's owners for Q3 2024 was CNY 13,931,460.39, compared to CNY 51,654,269.26 in the same period last year, a decrease of about 73.0%[17] Cash Flow - The operating cash flow for the year-to-date period increased significantly by 129.74% to ¥38,318,291.45[3] - Net cash flow from operating activities improved by 129.74% to ¥38,318,291.45, driven by accelerated customer payments and improved inventory turnover[9] - The cash flow from operating activities for the current period was CNY 2,431,301,554.79, down from CNY 3,107,444,951.09 in the previous year, indicating a decrease of approximately 21.8%[18] - The net cash flow from operating activities for Q3 2024 was 38,318,291.45 CNY, a significant improvement compared to -128,853,482.60 CNY in Q3 2023[19] - The company reported a total cash outflow from operating activities of 2,436,079,170.57 CNY, down from 3,391,258,205.22 CNY in the previous year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,694,786,201.77, reflecting a 0.46% increase from the previous year[3] - Total liabilities rose to CNY 849,058,831.78 from CNY 831,023,467.80, indicating an increase of approximately 2.7%[15] - The company's non-current assets totaled CNY 318,687,922.33, up from CNY 310,622,601.68, reflecting a growth of about 2.2%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period was 12,860[10] - The largest shareholder, Li Yanfei, holds 36.97% of shares, totaling 35,370,000 shares[11] - The total number of restricted shares at the beginning of the period was 54,371,875, with 21,353,065 shares released during the period[12] Expenses - The company's weighted average return on equity decreased to 0.22%, down by 0.23% compared to the previous year[3] - Financial expenses increased by 84.33% to ¥6,578,010.67 due to higher interest costs from increased borrowings[8] - Other income decreased by 55.81% to ¥1,391,409.14 primarily due to reduced government subsidies[8] - Research and development expenses for Q3 2024 were CNY 12,565,314.67, a slight decrease from CNY 14,122,063.35 in Q3 2023, reflecting a reduction of approximately 11.0%[16] - Sales expenses increased to CNY 180,912,080.87 in Q3 2024, compared to CNY 143,155,370.65 in Q3 2023, marking an increase of about 26.4%[16] Investment Activities - The company reported a net loss from investments of CNY 468,072.44 in Q3 2024, contrasting with a profit of CNY 403,817.23 in Q3 2023[16] - Cash flow from investing activities worsened by 99.79% to -¥24,940,175.33 due to increased investments in principal-protected financial products[9] - Total cash inflow from investing activities was 13,105,813.91 CNY, down from 16,220,277.06 CNY in the previous year[19] Government Subsidies - The company recognized a government subsidy of ¥191,540.64 during the reporting period, contributing to its non-recurring gains[4]

证券代码：300937 证券简称：药易购 公告编号：2024-037 四川合纵药易购医药股份有限公司 关于公司提起上诉暨诉讼进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）与杨亚、曹继军、 享健药易购健康科技有限公司（以下简称"享健公司"或"目标公司"）合同纠 纷本诉及反诉一案，公司于 2024 年 8 月 18 日收到广州市黄埔区人民法院出具的 《民事判决书》（（2022）粤 0112 民初 33048 号），具体内容详见公司于 2024 年 8 月 19 日披露的《关于公司收到民事判决书暨诉讼进展公告》（公告编号： 2024-034）。公司因不服一审判决，依法向广州市中级人民法院提起上诉，并于 近日收到广州市黄埔区人民法院送达的杨亚、曹继军、享健公司的《上诉状》。 现将有关情况公告如下： 一、公司提交上诉的基本情况 （一）案件当事人 3、判令被上诉人共同承担本案诉讼费。 二、对方提交上诉的基本情况 （一）案件当事人 上诉人：杨亚、曹继军、享健药易购健康科技有限公司 被上诉人：四川合纵药易购医药股份 ...

| 保荐人名称：申万宏源证券承销保荐有限责任公司 | 被保荐公司简称：药易购（300937） | | --- | --- | | 保荐代表人姓名：罗泽 | 联系电话：028-85958793 | | 保荐代表人姓名：何搏 | 联系电话：028-85958796 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2.督导公司建立健全并有效执行规章制度的情 | | | 况（1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 募集资金已于2023年使用完毕并销户 | | （2）公司募集资金项目进展是否与信息披露文 | 是 | | 件一致 | | | 4.公司治理督导情况 | | | （1）列席公 ...

证券代码：300937 证券简称：药易购 公告编号：2024-036 四川合纵药易购医药股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）依据中华人民共和 国财政部（以下简称"财政部"）发布的相关企业会计准则解释及规定要求变更 会计政策。根据《深圳证券交易所创业板股票上市规则》有关规定，本次会计政 策变更无需提交公司董事会及股东大会审议，现将具体情况公告如下： 一、会计政策变更情况概述 （一）变更原因 1、2023 年 8 月 1 日，财政部发布了《关于印发<企业数据资源相关会计处 理暂行规定>的通知》（财会〔2023〕11 号）（以下简称"《暂行规定》"）， 规定"企业数据资源相关会计处理"的内容，自 2024 年 1 月 1 日起施行。 （二）变更前采用的会计政策 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 （三）变更后采用的会计政策 本次会计政策变更后，公司将执 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan for the first half of 2024, representing a year-over-year growth of 15%[4]. - The company's operating revenue for the first half of 2024 was CNY 2,225,319,754.46, representing a 0.93% increase compared to CNY 2,204,845,065.75 in the same period last year[15]. - In the first half of 2024, the company's revenue reached 2.225 billion yuan, a year-on-year increase of 0.93%, while net profit attributable to shareholders was 12.0957 million yuan, a decline of 74.11%[22]. - The company's net profit attributable to shareholders decreased by 74.11% to CNY 12,095,746.45 from CNY 46,717,668.57 in the previous year[15]. - The total comprehensive income for the first half of 2024 was CNY 23,372,979.02, down from CNY 51,287,749.46 in the first half of 2023, representing a decrease of approximately 54.4%[142]. - The company's net profit for the first half of 2024 was ¥8,831,979.09, down from ¥56,989,412.01 in the previous year, marking a decrease of around 84.5%[138]. - The company's basic and diluted earnings per share fell by 73.47% to CNY 0.13 from CNY 0.49 in the previous year[15]. - The company reported a significant decline in non-recurring profit and loss, with a net profit of CNY 8,481,216.66, down 80.80% from CNY 44,163,173.51 in the previous year[15]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 5 million, which is a 20% increase compared to the same period last year[4]. - The company is expanding its market presence, targeting an increase in the number of retail locations by 25% over the next year[4]. - The company has established partnerships with over 1,800 pharmaceutical manufacturers, holding more than 12,000 pharmaceutical product distribution qualifications[24]. - The company aims to enhance its C-end reach and develop a new industrial model to improve pricing power and create a series of high-quality pharmaceutical products[22]. - The company is focusing on risk control in emerging business development, managing costs, and improving funding management during the cultivation period of the second growth curve[22]. Strategic Initiatives - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 10% to 15%[4]. - New product launches are expected to contribute an additional 200 million yuan in revenue by the end of 2024[4]. - The company plans to pursue strategic acquisitions to bolster its market position, with a budget of 500 million yuan allocated for potential deals[4]. - The company is actively investing in internet pharmaceutical retail projects, including the establishment of a B2C e-commerce operation base in Hangzhou[28]. - The company is exploring potential mergers and acquisitions to strengthen its market position[151]. Financial Management and Investments - Investment in new technology development has increased by 30%, focusing on enhancing supply chain efficiency[4]. - The company has established a credit system for small and micro customers, granting credit to 1,534 customers with a total credit amount of 25.53 million yuan during the reporting period[30]. - The company has set up a private equity fund to accelerate resource integration and investment opportunities in the pharmaceutical industry[29]. - The company has recognized data resources as intangible assets on the balance sheet, with a book value of 1,939,429.99 yuan as of the end of the reporting period[30]. - The company reported a total of 3,271.65 million CNY in related party transactions during the reporting period, with a maximum approved transaction amount of 19,320 million CNY[103]. Operational Challenges - The company has identified key risks, including intensified market competition and regulatory changes, which may impact future performance[3]. - The company's gross profit margin has decreased, influenced by a decline in retail scale in the pharmaceutical terminal market and a high comparable base from the previous year due to a public health event[22]. - The B2B e-commerce platform has seen a decrease in monthly active customers, leading to a decline in revenue, affected by regulatory requirements for unified management of retail chain headquarters[22]. - The company faces intensified market competition and changing demand, necessitating increased investment in promotions and R&D, which may not yield expected results[78]. Cash Flow and Financial Position - The net cash flow from operating activities improved significantly, reaching CNY 3,376,800.31, compared to a negative CNY 87,880,002.16 in the same period last year, marking a 103.84% increase[15]. - The company's cash and cash equivalents decreased by 72.43% to -¥55,734,803.18, mainly due to accelerated customer collections and improved inventory turnover[50]. - The total cash inflow from operating activities was CNY 1,714,242,712.44 in the first half of 2024, down from CNY 2,064,085,285.80 in the first half of 2023, representing a decrease of approximately 16.9%[143]. - The company reported a cash outflow of ¥1.45 billion for purchasing goods and services in the first half of 2024, compared to ¥1.89 billion in the previous year, reflecting a decrease of approximately 23.1%[145]. Corporate Governance and Compliance - The company has established a comprehensive management system and enhanced its internal processes to support long-term strategic development[43]. - The company emphasizes strict compliance with e-commerce laws and consumer protection regulations to mitigate risks in information security and business ethics[42]. - The company has maintained a commitment to transparency and accurate information disclosure, ensuring that shareholders are informed of significant matters[90]. - The financial report was approved by the board on August 27, 2024, ensuring compliance with accounting standards[160]. Research and Development - The company aims to enhance its research and development capabilities to drive future growth[151]. - Research and development investment decreased by 10.13% to ¥11,033,371.43, primarily due to reduced MAH R&D expenditures[50]. - The company has initiated research and development for new technologies aimed at enhancing operational efficiency and product offerings[180]. - The company is focusing on research and development of new products to strengthen its market position[159].

证券代码：300937 证券简称：药易购 公告编号：2024-034 四川合纵药易购医药股份有限公司 关于公司收到民事判决书暨诉讼进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 公司近日收到广州市黄埔区人民法院出具的《民事判决书》（（2022）粤 0112 民初 33048 号），判决如下： 1、案件所处的诉讼阶段：一审判决； 2、公司所处的当事人地位：被告、反诉原告； 3、涉案的金额：判决金额人民币 4,400 万元及相关费用； 4、对公司损益产生的影响：本次判决为一审判决，最终诉讼、执行结果及 对公司本期及期后利润的影响存在不确定性，敬请投资者注意投资风险。 一、本次诉讼事项的基本情况 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2022 年 11 月 10 日收到广东省广州市黄埔区人民法院送达的《民事起诉状》《应诉通知书》等 法律文书，原告杨亚、曹继军以公司为被告提起民事诉讼，具体内容详见公司在 巨潮资讯网（www.cninfo.com.cn）披露的《关于公司收到民事起诉状的公告》（公 告编号：2022-072）。 原 ...

证券代码：300937 证券简称：药易购 公告编号：2024-033 四川合纵药易购医药股份有限公司 关于签署《关于设立及收购目标公司之合作框架协议》的 进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2021 年 10 月 17 日召开第二届董事会 2021 年第六次会议审议通过了《关于签署<关于设立及 收购目标公司之合作框架协议>的议案》，公司拟与自然人杨亚、曹继军（以下 统称"乙方"）围绕享健药易购健康科技有限公司（以下简称"目标公司"）进行股 权合作。乙方为广州逸生汇商贸有限公司（下称"逸生汇"）、广州沁威网络科技 有限公司（下称"沁威"）、广州市享健贸易有限公司（下称"享健"）实际控制人 及股东，逸生汇、沁威、享健主要从事健康产品的网络销售及信息服务等方面业 务。乙方同意设立目标公司，并由目标公司对逸生汇、享健和沁威三家公司进行 资产、业务及人员整合重组，公司有意向以现金方式购买目标公司全体股东所持 目标公司 51%的股权。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn ...

Group 1: Company Overview - Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. is actively exploring new industrial models, focusing on MAH, OEM, and CRO sectors to enhance its pharmaceutical ecosystem [2] - The company has established subsidiaries such as Jinpeifang and Hezhong Zehui to support its pharmaceutical licensing and development efforts [3] - The company aims to optimize its product structure and improve gross profit margins by increasing the number and quality of held licenses and product specifications [3] Group 2: Sales and Marketing Strategy - The company is exploring offline retail as a traffic entry point, aiming to diversify its service offerings and develop chronic disease management services [3] - An "AI Membership" retail model is being promoted to enhance sales while maintaining the integrity of the pharmaceutical supply chain [3] - The company is transitioning its sales model from treating diseases to preventive health, focusing on a broader range of health products [3] Group 3: Competitive Advantage and Future Direction - The core competitive advantages include innovative internet and big data technologies, a comprehensive pharmaceutical service ecosystem, and extensive upstream channel resources [4] - The company has built a C-end operational team and system to leverage its core competencies and cultivate a second growth curve [4] - The first growth curve has provided the company with leading technical strength and infrastructure capabilities, which are essential for its future development [4]